Evidence map›Paper›PMID 29572766›Full record

ArticleInternational journal of hematology2018

CD3

Yayoi Ando, Akiko Miyagi Maeshima, Suguru Fukuhara, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Hirokazu Taniguchi, Koji Izutsu

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yayoi AndoDivision of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Akiko Miyagi MaeshimaDivision of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. akmaeshi@ncc.go.jp.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shinichi MakitaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Tatsuya SuzukiDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hirokazu TaniguchiDivision of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

Japan Agency for Medical Research and Development Fund 17ck0106349s0201
6 · The paper itself

Abstract

We present a case of atypical extraosseous plasmacytoma (EP) with a plasmablastic morphology and CD3

Indexed as

CD3 ComplexCD56 AntigenRNA, ViralAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclophosphamideDiagnosis, DifferentialDoxorubicinHerpesvirus 4, HumanHumansMaleMiddle AgedNasal CavityNose NeoplasmsPhenotypePlasmacytomaBiomarkers, TumorCD3 ComplexCD56 AntigenCyclophosphamideDoxorubicinEpstein-Barr virus encoded RNA 1NCAM1 protein, humanPrednisoloneRNA, ViralSDC1 protein, humanSyndecan-1VincristineCD3CD56Epstein–Barr virusNasal cavityPlasmacytoma

Identifiers

PMID29572766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.